Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

60%

3 of 5 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 2
2(50.0%)
Phase 1
1(25.0%)
N/A
1(25.0%)
4Total
Phase 2(2)
Phase 1(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05178134Phase 2Completed

A Phase 2 Bridging Study to Assess the New Formulation of ETVAX

Role: lead

NCT06290089Not ApplicableCompleted

Pre-Study of Wild Type Enterotoxigenic E. Coli (ETEC) Strain for Verification of a Planned Challenge Dose

Role: lead

NCT04838587Completed

An Epidemiological Surveillance Study to Determine the Incidence of ETEC in Children and Infants in Lusaka

Role: collaborator

NCT03729219Phase 2Completed

Prevention of Diarrheal Disease Due to Infection With Enterotoxigenic E. Coli (ETEC)

Role: lead

NCT02531802Phase 1Completed

Enterotoxigenic Escherichia Coli (ETEC) ETVAX Vaccine Trial in Bangladesh

Role: collaborator

All 5 trials loaded